Also known as Cagrilintide/semaglutide · cagrilintide + semaglutide
Novo Nordisk’s investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1) — two appetite pathways in one weekly injection.
Research refreshed
CagriSema is not a single molecule but a fixed-dose combination of two peptides already in this catalog: cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 agonist. Novo Nordisk pairs the amylin and GLP-1 satiety pathways in one once-weekly injection, betting that two complementary appetite mechanisms together drive more weight loss than either alone. It is investigational and in Phase 3.
CagriSema is a combination product, and that is the whole point of it. Rather than engineer a single peptide that hits several receptors — the multi-agonist route taken by tirzepatide and retatrutide — Novo Nordisk co-formulates two of its existing peptides: the amylin analog cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite, but through different receptor systems, so combining them is studied for additive weight effect from a single weekly injection.
Because it is a co-formulation, CagriSema has no molecular formula or sequence of its own — its properties are those of its two components, each documented on its own monograph here. It is investigational, studied in the Phase 3 REDEFINE program, where it produced large mean weight reductions in the low-to-mid twenties percent; the results were strong in absolute terms even as they were scrutinized against very high market expectations. It is not FDA-approved.
Co-agonism across two pathways: semaglutide activates the GLP-1 receptor while cagrilintide activates amylin and calcitonin receptors — complementary routes to satiety and slowed gastric emptying.
Behind every vial of CagriSema is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CagriSema, specifically, is brought into being.
CagriSema begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
CagriSema is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — CagriSema plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of CagriSema proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CagriSema — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
CagriSema is a co-formulation, not a synthesized molecule: it is manufactured by making its two component peptides — cagrilintide and semaglutide — separately, each to its own spec and certificate of analysis, and combining them at fixed doses. Its quality therefore rests on the identity and purity of two peptides at once, described on their individual monographs.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning CagriSema, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
CagriSema is Novo Nordisk’s investigational fixed combination of two peptides — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — given as one once-weekly injection for weight management.
No — it is a co-formulation of two separate peptides (cagrilintide and semaglutide), each with its own monograph here, so it has no single molecular formula.
Tirzepatide is one molecule hitting two receptors (GIP + GLP-1); CagriSema instead combines two molecules (amylin + GLP-1). Both aim for additive metabolic effect by different means.
No — it is investigational and in Phase 3. This page is a research and educational reference, not medical advice.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.